TerminatedPhase 2NCT03620149

Reduced Dose-density of Denosumab for Unresectable GCTB

Studying Giant cell tumor of bone

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Principal Investigator
Emanuela Palmerini, MD, PhD
IRCCS Instituto Ortopedico Rizzoli
Intervention
Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA](drug)
Enrollment
2 target
Eligibility
18 years · All sexes
Timeline
20192020

Study locations (8)

Collaborators

Amgen

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03620149 on ClinicalTrials.gov

Other trials for Giant cell tumor of bone

Additional recruiting or active studies for the same condition.

See all trials for Giant cell tumor of bone

← Back to all trials